Segment Information - Reportable Segment Information (Detail) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Net sales:
Net sales	$ 3,027	$ 3,226
Segment Adjusted Operating EBITDA:
Adjusted Operating EBITDA	503	702
Other Depreciation and Amortization	276	303
Interest expense	(111)	(72)
Other (expense) income, net	(6)	16
Restructuring and other charges, net	(52)	(2)
Acquisition, divestiture, and integration related costs	31	49
Strategic initiative costs	(13)	0
Regulatory costs	(5)	0
Other gains (losses)	(5)	7
Income before taxes	14	285
Business divestiture costs	(21)	(30)
Nourish
Segment Adjusted Operating EBITDA:
Restructuring and other charges, net	(30)	(2)
Health & Biosciences
Segment Adjusted Operating EBITDA:
Restructuring and other charges, net	(10)	0
Scent
Segment Adjusted Operating EBITDA:
Restructuring and other charges, net	(10)	0
Pharma Solutions
Segment Adjusted Operating EBITDA:
Restructuring and other charges, net	(2)	0
Corporate and Other
Segment Adjusted Operating EBITDA:
Restructuring and other charges, net	(52)	(2)
Integration-related costs	(10)	(18)
Transaction related costs		(1)
Operating Segments | Nourish
Net sales:
Net sales	1,653	1,731
Segment Adjusted Operating EBITDA:
Segment Adjusted Operating EBITDA	208	329
Operating Segments | Health & Biosciences
Net sales:
Net sales	513	661
Segment Adjusted Operating EBITDA:
Segment Adjusted Operating EBITDA	131	192
Operating Segments | Scent
Net sales:
Net sales	608	585
Segment Adjusted Operating EBITDA:
Segment Adjusted Operating EBITDA	105	116
Operating Segments | Pharma Solutions
Net sales:
Net sales	253	249
Segment Adjusted Operating EBITDA:
Segment Adjusted Operating EBITDA	$ 59	$ 65